Blackrock, INC Schedule 13G passive stakes
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, reporting a 7.1% beneficial ownership stake in Bandwidth Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 9.9% beneficial ownership stake in BlueLinx Holdings Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Boosts Stake in Blueprint Medicines Corp to 8.0%
BlackRock, Inc. has disclosed an increased passive ownership stake of 8.0% in Blueprint Medicines Corp, holding over 5 million shares as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.7% beneficial ownership stake in Business First Bancshares, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Cardiff Oncology, Inc.
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 8.2% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 12.8% of Clearwater Paper Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.9% passive beneficial ownership stake in CommScope Holding Company, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Passive Stake in ConnectOne Bancorp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% passive beneficial ownership stake in ConnectOne Bancorp Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in Flex LTD Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.2% of Flex LTD's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Amicus Therapeutics, Disclosing 7.4% Ownership
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Amicus Therapeutics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 7.8% Stake in Arcturus Therapeutics, Files Updated Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, confirming its beneficial ownership of 7.8% of Arcturus Therapeutics Holdings Inc. common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in Ares Management Corporation as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Arrowhead Pharmaceuticals, Disclosing 13.8% Beneficial Ownership
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.0% beneficial ownership stake in Assurant, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.1% Passive Stake in Atea Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Atea Pharmaceuticals, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.95% beneficial ownership stake in Atlantic Union Bankshares Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, revealing a beneficial ownership of 15.9% of Avista Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 6.7% of Credo Technology Group Holding Ltd's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, reporting a 7.6% beneficial ownership stake in Patria Investments Limited as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, reporting a beneficial ownership of 8.5% in StoneCo Ltd.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.6% Stake in XP Inc. Class A Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.6% of XP Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, disclosing a passive beneficial ownership of 8.1% in Genco Shipping & Trading Ltd.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.8% Passive Stake in Coca-Cola FEMSA
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.8% passive beneficial ownership stake in Coca-Cola FEMSA SAB de CV as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.5% Stake in CEMEX SAB DE CV Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.5% of CEMEX SAB DE CV's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.2% beneficial ownership stake in STMicroelectronics N.V. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 9 to its Schedule 13G, reporting a 6.7% beneficial ownership stake in ASML Holding NV as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 7.9% beneficial ownership stake in CNH Industrial N.V. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% passive beneficial ownership stake in Seagate Technology Holdings Public Limited Company as of March 31, 2025.